Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previous participation in the TMC114-C202 or TMC114-C213 trials~* Significant virologic failure during participation in the above trials~* Study participation in the treatment phase of the original trial for a total of at least 12 weeks before TMC114-C215 screening~* Patient agrees to take TMC114/RTV with at least 2 other antiretrovirals (NRTIs), with or without T-20, from baseline onwards~* Patient has given informed consent~Exclusion Criteria:~* Use of disallowed concomitant therapy~* Patient with clinical or laboratory evidence of active liver disease, liver impairment/ dysfunction or cirrhosis irrespective of liver enzyme levels~* Any active or unstable medical condition that, in the investigator's opinion, would compromise the subject's safety~* Patient with laboratory abnormalities at screening as defined by ACTG grading scheme as listed in the protocol~* Patient withdrawing consent from TMC114-C202 or TMC114-C213

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): TMC114600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available

Based on this trial design, predict the completion outcome and termination type (if applicable).